Product description
ODN-2007 is a Toll-like receptor 9 (TLR9)-targeting immunostimulatory oligonucleotide active pharmaceutical ingredient (API) and a next-generation core material for precise innate immune activation, offering high safety and stable biological activity. Unlike broad-spectrum immune stimulants, ODN-2007 specifically activates the TLR9 receptor, precisely initiating downstream immune signaling pathways and efficiently inducing the secretion of multiple cytokines, including interferons and interleukins. It provides balanced activation of innate immune responses with minimal excessive immune stimulation, low risk of adverse effects, and excellent biocompatibility.
Manufactured using a proprietary precision chemical synthesis and purification process, the product achieves a purity of ≥98%, with trace residual impurities strictly controlled in accordance with the highest industry quality standards. It demonstrates excellent batch-to-batch consistency, outstanding aqueous solubility, stable physicochemical properties, and highly uniform biological activity, delivering substantially higher quality than conventionally synthesized oligonucleotide materials.
Produced on standardized GMP-compliant manufacturing lines, the product can be supplied with a complete Certificate of Analysis (COA), comprehensive impurity profiles, and regulatory documentation to support research, process development, and large-scale manufacturing of immune activation reagents, vaccine adjuvant formulations, and immunomodulatory biologics.
ODN-2007 efficiently activates macrophages, promotes the expression of key immune mediators including IFN-γ, IL-6, and IL-1β, enhances host resistance against infectious diseases, and helps maintain immune and inflammatory homeostasis. It combines precise immune activation, immune enhancement, anti-infective protection, and vaccine adjuvant potentiation, making it a high-quality intermediate for immunopharmacology research, next-generation vaccine adjuvant development, and innovative immunomodulatory therapeutics.
This product is intended solely for research use and as a biopharmaceutical intermediate and is not intended for direct human use.